帕罗西汀联合喹硫平与单用帕罗西汀治疗双重抑郁症的疗效及安全性

谷伟，赵建民，张敏，张海风

（陕西省汉中市精神病医院，陕西 汉中，723003）

浏览次数：138次 下载次数：315次

摘要：

目的 比较帕罗西汀联合喹硫平与单用帕罗西汀治疗双重抑郁症的疗效及安全性。方法 选取我院收治的双重抑郁症患者84例为研究对象，随机分为研究组和对照组，各42例。研究组患者给予帕罗西汀联合喹硫平治疗，对照组患者单纯给予帕罗西汀治疗。比较两组患者的的HAMD焦虑、抑郁评分、CGI-S评分、TESS评分、治疗总有效率、不良反应发生情况及每日药物使用剂量。结果 治疗后2、4、6、8、12 周，两组患者的HAMD抑郁及焦虑评分明显优于治疗前（P<0.05）；治疗后4、6、8、12 周，研究组患者的HAMD抑郁评分明显优于对照组（P<0.05）；治疗后2、4、6、8、12 周，研究组患者的HAMD焦虑评分明显优于对照组（P<0.05）。治疗后4、6、8、12 周，两组患者的CGI-S评分均明显低于治疗前，且研究组患者CGI-S 评分明显低于 对照组（P<0.05）。研究组患者治疗总有效率明显高于对照组患者（P<0.05）。两组患者TESS评分及不良反应总发生率比较， 差异无统计学意义（P>0.05）。研究组患者帕罗西汀每日平均剂量显著低于对照组（P<0.05）。结论 帕罗西汀联合喹硫平治疗双重抑郁症的疗效优于单用帕罗西汀治疗，起效更快，安全性更高，值得临床推广应用。

关键词：帕罗西汀；喹硫平；双重抑郁症；汉密顿抑郁、焦虑评分

中图分类号：R749.4文献标志码：A文章编号：2096-1413(2017)27-0003-03

Clinical effect and safety of paroxetine combined with quetiapine and paroxetine alone in the treatment

of double depression
GU Wei, ZHAO Jian-min, ZHANG Min, ZHANG Hai-feng


(Hanzhong Mental Hospital, Hanzhong 723003, China)

ABSTRACT: Objective To compare the clinical effect and safety of paroxetine combined with quetiapine and paroxetine alone in the treatment of double depression. Methods Eighty-four double depression patients were selected and randomly divided into study group and control group, with 42 cases in each group. The study group received paroxetine combined with quetiapine, and the control group was given the paroxetine alone. The HAMD depression and anxiety scores, CGI-S scores, TESS scores, total effective rates, incidences of adverse reactions and daily drug use dose were compared between the two groups. Results At 2, 4, 6, 8 and 12 weeks after treatment, the HAMD depression and anxiety scores of the two groups were better than those before treatment (P<0.05). At 4, 6, 8 and 12 weeks after treatment, the HAMD depression scores of the study group were better than those of the control group (P<0.05). At 2, 4, 6, 8 and 12 weeks after treatment, the HAMD anxiety scores of the study group were better than those of the control group (P<0.05). At 4, 6, 8 and 12 weeks after treatment, the CGI-S scores of the two groups were lower than those before treatment, and those of the study group were lower than the control group (P<0.05). The total effective rate of the study group was higher than that of the control group (P<0.05). There were no significant differences in TESS score and incidence of adverse reaction between the two groups (P>0.05). The daily drug use dose of paroxetine in the study group was lower than that in the control group (P<0.05). Conclusion The efficacy of paroxetine combined with quetiapine in the treatment of double depression is better than that of paroxetine alone. It has faster onset and higher safety, which is worthy of clinical application and promotion.
KEYWORDS: paroxetine; quetiapine; double depression; HAMD depression and anxiety scores

参考文献：
[1] 沈渔邨.精神病学[M].5 版.北京:人民卫生出版社,2009.
[2] 李松芝,伊茂森.双重抑郁症研究进展[J].国际精神病学杂志,2002,29(1):17-20.
[3] 汤毓华.汉密顿抑郁量表(HAMD)[J].中国心理卫生杂志,1999(s1):220-223.
[4] 王新法,吴焕,娄涛.帕罗西汀合用喹硫平治疗双重抑郁症的随机开放试验[J].中国心理卫生杂志,2011,25(3):196-199.
[5] 张明园.精神科评定量表手册[M].2 版.长沙:湖南科学技术出版社,1998.
[6] 严保平,崔利军,孙秀丽,等.河北省双重抑郁症的患病率、临床特征及社会功能状况分析[J].中国神经精神疾病杂志,2010,36(10):612-615.
[7] RUSH AJ,KRAEMER HC,SACKEIM HA,et al.Report by the AC -NP task force on response and remission in major depressive disorder[J]. Neuro Psychopharmacology,2006,31(9):1841-1853.
[8] WEISLER R,JOYCE M,MCGILL L,et al.Extended release quetiapine fumarate mono therapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study[J].CNS Spectr,2009,14 (6):299-313.
[9] 雷秋红.评价帕罗西汀合用喹硫平治疗双重抑郁症的疗效和安全性[J].医学信息,2016,29(3):129-130.
[10] 张云河.帕罗西汀合用喹硫平治疗双重抑郁症48例临床效果观察[J].世界最新医学信息文摘:连续型电子期刊,2016,16(1):27-28.
[11] 龚日东,黄书梅.帕罗西汀合用喹硫平治疗双重抑郁症的疗效和安全性分析[J].中国实用医刊,2015,42(13):67-68.